Scott D Wardwell
Overview
Explore the profile of Scott D Wardwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang W, Li F, Gong Y, Zhang Y, Youngsaye W, Xu Y, et al.
Bioorg Med Chem Lett
. 2022 Nov;
80:129084.
PMID: 36423823
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this...
2.
Gonzalvez F, Vincent S, Baker T, Gould A, Li S, Wardwell S, et al.
Cancer Discov
. 2021 Feb;
11(7):1672-1687.
PMID: 33632773
Most exon 20 insertion (ex20ins) driver mutations in non-small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting...
3.
Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al.
Clin Cancer Res
. 2016 Nov;
22(22):5527-5538.
PMID: 27780853
Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary...
4.
Huang W, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al.
J Med Chem
. 2016 May;
59(10):4948-64.
PMID: 27144831
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance...
5.
Squillace R, Miller D, Wardwell S, Wang F, Clackson T, Rivera V
Int J Oncol
. 2012 May;
41(2):425-32.
PMID: 22614157
Although androgen ablation therapy is the foundation of current prostate cancer treatment, most patients ultimately develop castration-resistant disease. One proposed mechanism to account for androgen receptor (AR) activity in the...
6.
Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell S, et al.
Chem Biol Drug Des
. 2011 Nov;
78(6):999-1005.
PMID: 22034911
Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizotinib, a dual MET/ALK inhibitor, has...
7.
Squillace R, Miller D, Cookson M, Wardwell S, Moran L, Clapham D, et al.
Mol Cancer Ther
. 2011 Oct;
10(10):1959-68.
PMID: 21825008
Ridaforolimus is a nonprodrug rapamycin analogue that potently inhibits mTOR and has shown significant activity in patients with metastatic sarcoma and endometrial cancer, two diseases where high unmet need remains....
8.
Rivera V, Squillace R, Miller D, Berk L, Wardwell S, Ning Y, et al.
Mol Cancer Ther
. 2011 Apr;
10(6):1059-71.
PMID: 21482695
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation....